These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 31961035)

  • 61. Lupus anticoagulants associated inhibitor against factor IX in a young patient with haemophilia B.
    Barnbrock A; Heller C; Königs C; Budde U; Schwabe D
    Haemophilia; 2016 Sep; 22(5):e437-9. PubMed ID: 27353656
    [No Abstract]   [Full Text] [Related]  

  • 62. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia.
    Mathias M; Khair K; Hann I; Liesner R
    Br J Haematol; 2004 May; 125(3):366-8. PubMed ID: 15086418
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Gene deletions in patients with haemophilia B and anti-factor IX antibodies.
    Giannelli F; Choo KH; Rees DJ; Boyd Y; Rizza CR; Brownlee GG
    Nature; 1983 May 12-18; 303(5913):181-2. PubMed ID: 6843667
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Successful induction of immune tolerance with FIX recombinant in a patient with haemophilia B with inhibitor.
    Soto I; Vicente JM; Corte JR; Urgellés MF; Pinto CR
    Haemophilia; 2004 Jul; 10(4):401-4. PubMed ID: 15230957
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Management of haemophilia B inhibitor patients with anaphylactic reactions to FIX concentrates.
    Shibata M; Shima M; Misu H; Okimoto Y; Giddings JC; Yoshioka A
    Haemophilia; 2003 May; 9(3):269-71. PubMed ID: 12694516
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Management of factor VIII inhibitors: evolution and current status.
    Bloom AL
    Haemostasis; 1992; 22(5):268-75. PubMed ID: 1478538
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors.
    Arkin S; Blei F; Fetten J; Foulke R; Gilchrist GS; Heisel MA; Key N; Kisker CT; Kitchen C; Shafer FE; Shah PC; Strickland D
    Blood Coagul Fibrinolysis; 2000 Apr; 11(3):255-9. PubMed ID: 10870806
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors.
    Matino D; Makris M; Dwan K; D'Amico R; Iorio A
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD004449. PubMed ID: 26677005
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Characterization of heterogeneity of haemophilia B for the detection of carriers.
    Panicucci F; Sagripanti A; Conte B; Pinori E; Vispi M; Lecchini L
    Haemostasis; 1980; 9(5):310-8. PubMed ID: 6157611
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Inhibitor incidence in previously untreated patients with severe haemophilia B: a systematic literature review.
    Franchini M; Santoro C; Coppola A
    Thromb Haemost; 2016 Jul; 116(1):201-3. PubMed ID: 27052668
    [No Abstract]   [Full Text] [Related]  

  • 71. Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors.
    Astermark J; Rocino A; Von Depka M; Van Den Berg HM; Gringeri A; Mantovani LG; Morado M; Garrido RP; Schiavoni M; Villar A; Windyga J;
    Haemophilia; 2007 Jan; 13(1):38-45. PubMed ID: 17212723
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Immunological heterogeneity of haemophilia B: a multicentre study of 98 kindreds.
    Parekh VR; Mannucci PM; Ruggeri ZM
    Br J Haematol; 1978 Dec; 40(4):643-55. PubMed ID: 103564
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Inhibitor development in haemophilia B: an orphan disease in need of attention.
    DiMichele D
    Br J Haematol; 2007 Aug; 138(3):305-15. PubMed ID: 17614818
    [TBL] [Abstract][Full Text] [Related]  

  • 74. An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan.
    Shirahata A; Fukutake K; Higasa S; Mimaya J; Oka T; Shima M; Takamatsu J; Taki M; Taneichi M; Yoshioka A;
    Haemophilia; 2011 Sep; 17(5):771-6. PubMed ID: 21682824
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cyclosporin A can achieve immune tolerance in a patient with severe haemophilia B and refractory inhibitors.
    Cross DC; Van Der Berg HM
    Haemophilia; 2007 Jan; 13(1):111-4. PubMed ID: 17212737
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors.
    Young G; McDaniel M; Nugent DJ
    Haemophilia; 2005 May; 11(3):203-7. PubMed ID: 15876264
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies.
    Holme PA; Brosstad F; Tjønnfjord GE
    Haemophilia; 2005 Sep; 11(5):510-5. PubMed ID: 16128896
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Detection of carriers of haemophilia B.
    Orstavik KH; Veltkamp JJ; Bertina RM; Hermans J
    Br J Haematol; 1979 Jun; 42(2):293-301. PubMed ID: 465373
    [TBL] [Abstract][Full Text] [Related]  

  • 79. How to manage invasive procedures in children with haemophilia.
    Ljung RC; Knobe K
    Br J Haematol; 2012 Jun; 157(5):519-28. PubMed ID: 22390160
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
    Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E
    Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.